JP2024532303A5 - - Google Patents

Info

Publication number
JP2024532303A5
JP2024532303A5 JP2024512133A JP2024512133A JP2024532303A5 JP 2024532303 A5 JP2024532303 A5 JP 2024532303A5 JP 2024512133 A JP2024512133 A JP 2024512133A JP 2024512133 A JP2024512133 A JP 2024512133A JP 2024532303 A5 JP2024532303 A5 JP 2024532303A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532303A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/057951 external-priority patent/WO2023026222A1/en
Publication of JP2024532303A publication Critical patent/JP2024532303A/ja
Publication of JP2024532303A5 publication Critical patent/JP2024532303A5/ja
Pending legal-status Critical Current

Links

JP2024512133A 2021-08-25 2022-08-25 神経炎症性障害の治療 Pending JP2024532303A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121038491 2021-08-25
IN202121038491 2021-08-25
PCT/IB2022/057951 WO2023026222A1 (en) 2021-08-25 2022-08-25 Treatment for neuroinflammatory disorders

Publications (2)

Publication Number Publication Date
JP2024532303A JP2024532303A (ja) 2024-09-05
JP2024532303A5 true JP2024532303A5 (https=) 2025-09-02

Family

ID=85322831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512133A Pending JP2024532303A (ja) 2021-08-25 2022-08-25 神経炎症性障害の治療

Country Status (6)

Country Link
EP (1) EP4392413A4 (https=)
JP (1) JP2024532303A (https=)
KR (1) KR20240052009A (https=)
CN (1) CN117858871A (https=)
CA (1) CA3226855A1 (https=)
WO (1) WO2023026222A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2024281828A1 (en) * 2023-06-02 2025-12-04 Zydus Lifesciences Limited Treatment for amyotrophic lateral sclerosis (als)
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11465992B2 (en) * 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
CN120208846A (zh) * 2019-01-14 2025-06-27 载度思生命科学有限公司 经取代的磺酰脲类衍生物

Similar Documents

Publication Publication Date Title
JP2024532303A5 (https=)
JP2022533311A5 (https=)
JP2023518830A5 (https=)
JP2022153638A5 (https=)
JP2022543155A5 (https=)
JP2016128414A (ja) ピリミジン誘導体の製造プロセス
JP2013523733A5 (https=)
JP2014532638A5 (https=)
RU2749189C2 (ru) Композиции и способы лечения ксеростомии
US20230173077A1 (en) Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals
JP2019524834A5 (https=)
JP2024509820A5 (https=)
JP2024504252A5 (https=)
SI3082773T1 (en) Oral formulations of pyrrolidine derivatives
CA3089894A1 (en) Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
JP2024512425A5 (https=)
JP2001131075A (ja) 抗hiv剤
JP2024541569A5 (https=)
DK2555776T3 (en) Combination Compositions of Adenosine A1 Agonists and Non-Selective Beta-Adrenoreceptor Blockers to Reduce Intraocular Pressure
JP2025502064A5 (https=)
WO2011119919A1 (en) Adenosine compounds and their use thereof
ES2214712T3 (es) Hemisulfato nucleosido carbociclico y su uso en el tratamiento de infecciones viricas.
JP2024524572A5 (https=)
RU2017131522A (ru) (2s,4r)-5-(5'-хлор-2'-фторбифенил-4-ил)-2-этоксиоксалиламино)-)-2-гидроксиметил-2-метилпентановая кислота
US8440639B2 (en) Combination compositions for reducing intraocular pressure